Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
Holding EXAS?
Track your performance easily
EXAS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$40.62 - $85.71
Previous Close$61.69
Volume2.20M
Average Volume (3M)2.70M
Market Cap
$11.50B
Enterprise Value$13.32B
Total Cash (Recent Filing)$946.78M
Total Debt (Recent Filing)$2.76B
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Oct 30, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding184,769,862
10 Day Avg. Volume1,711,642
30 Day Avg. Volume2,695,698
Standard Deviation0.15
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-11.30
Price to Sales (P/S)4.40
Price to Cash Flow (P/CF)26.90
P/FCF Ratio40.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.10
Enterprise Value/Gross Profit7.22
Enterprise Value/Ebitda209.56
Forecast
1Y Price Target
$78.00Price Target Upside26.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Exact Sciences News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEXAS delivered strong profitability, with adj EBITDA coming in significantly above expectations at $100M.
Pipeline MilestonesSeveral pipeline milestones expected before year-end could be catalysts for the stock, such as Cologuard-Plus FDA approval and initial blood-based CRC screening data from Blue-C cohort.
Sales Force ExpansionManagement indicated they completed sales force expansion in May and expects full productivity in 6 months — driving the contribution growth.
Bears Say
Product DataIncreased uncertainty over EXAS CG blood given lack of any data and delayed disclosures.
Sales Force ProductivityIt appears that Everett's departure was agreed upon and not reflective of performance, but it's hard for investors to ignore the sales force productivity related growth challenges that the company faced recently.
Target AchievementThe stock has been weak as concerns about achieving targets and the impact from Blood have grown.
---
Ownership Overview
3.24% Insiders
42.54% Mutual Funds
52.59% Other Institutional Investors
1.63% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $40.62 and its highest was $85.71 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Currently, no data Available
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Oct 30, 2024 which is in 60 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Jul 31, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.25.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -$0.19.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 184,769,870 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went up 26.773%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Among the largest hedge funds holding Exact Sciences Corp.’s share is Glenview Capital Management LLC. It holds Exact Sciences Corp.’s shares valued at 27M.
---
Exact Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.00 (26.44% Upside)
$78.00 (26.44% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.51%
12-Months-Change
Fundamentals
Return on Equity
-5.60%
Trailing 12-Months
Asset Growth
5.00%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
---
EXAS Company Deck
---
EXAS Earnings Call
Q2 2024
0:00 / 0:00
---
EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
---
EXAS Stock 12 Month Forecast
Average Price Target
$78.00
▲(26.44% Upside)
Technical Analysis
Best Analysts Covering EXAS
1 Year
1 Year Success Rate
15/20 ratings generated profit
1 Year Average Return
+35.64%
initiated a buy rating 9 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +35.64% per trade.
---